Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
Targeting Adhesion Molecules With ADC's: The Bet Of CytomX
04:04am, Tuesday, 11'th Nov 2025
CytomX (CTMX) is advancing its ADC candidate CX-2051 in the oncological field. CX-2051 shows an impressive response rate and improved progression-free survival in heavily pretreated colorectal cancer
CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript
02:26pm, Friday, 07'th Nov 2025
CytomX Therapeutics, Inc. ( CTMX ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Chris Ogden - SVP & Chief Financial Officer Sean McCarthy - Chairman & CEO Conference Call Pa
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
08:01pm, Thursday, 06'th Nov 2025
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.07 per share a year ago.
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
04:10pm, Thursday, 06'th Nov 2025
- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 s
Top Biotech Stocks Riding The Rally
03:15pm, Tuesday, 04'th Nov 2025
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock pric
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
08:00am, Thursday, 30'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wil
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
04:05pm, Monday, 20'th Oct 2025
Leadership team addition to drive strategic long-term value creation and partnering strategy Leadership team addition to drive strategic long-term value creation and partnering strategy
CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible
11:45pm, Monday, 13'th Oct 2025
CytomX Therapeutics presents a trade opportunity centered on upcoming Q1'26 clinical data for its masked, EpCAM-targeting, antibody-drug conjugate. Previous phase 1 data showed a compelling response r
Renewed Tariff Fears Spotlight Top Performing Stocks Since April
05:00am, Sunday, 12'th Oct 2025
Tariff fears have returned to markets just as stocks passed the six-month mark from April's "Liberation Day" bottom. In this article, I look back to find the highest performing stocks since the big Ap
CytomX: A Fresh Start With New Drugs After Total Pipeline Failure
11:20am, Monday, 06'th Oct 2025
CytomX Therapeutics pivots to focus on CX-2051 for metastatic colorectal cancer after terminating prior clinical candidates and restructuring operations. CX-2051 shows promising early Phase 1 efficacy
Why CytomX Therapeutics Stock Was Skyrocketing This Week
08:08am, Friday, 26'th Sep 2025
It isn't difficult for a modestly priced stock to leap in value on a positive news item. That's the dynamic behind the monster rise these past few days of clinical-stage biotech CytomX Therapeutics (C
CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
04:26pm, Wednesday, 10'th Sep 2025
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Sean McCarthy - Chairman & CEO Conference Call Part
CytomX Therapeutics to Present at Upcoming September Investor Conferences
08:00am, Thursday, 28'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
08:00am, Wednesday, 13'th Aug 2025
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active a
